Pharmaspective

The Trend Towards Global Transparency: A Challenging New World for the Life Sciences Industry

Please click here to view a copy of “The Trend Towards Global Transparency: A Challenging New World for the Life Sciences Industry,” prepared by D. Jeffrey Campbell and Brian P. Sharkey for distribution at CBI’s 6^th Annual Forum on Sunshine and Aggregate Spend.  

For additional information on the authors, please click on their names below:

D. Jeffrey Campbell, Esq., Principal, Porzio, Bromberg and Newman, P.C.

Brian P. Sharkey, Esq., Counsel, Porzio, Bromberg and Newman, P.C.

AdvaMed, PhRMA and Other Industry Organizations Encourage CMS to “Promptly Publish” the Final Rule Implementing the Sunshine Act

On August 14, 2012, several industry organizations, including the Advanced Medical Technology Association (AdvaMed) and the Pharmaceutical Research and Manufacturers of America (PhRMA), sent a joint letter to Marilyn Travenner, Acting Administrator at the Centers for Medicare and Medicaid Services (CMS), encouraging CMS to “promptly publish” the final rule implementing the Sunshine Act provisions of the Patient Protection and Affordable Care Act. In addition, the organizations request that CMS provide applicable manufacturers 180 days after the final rule is published before requiring data collection. The organizations believe that its member companies will need this additional time to “properly implement the data collection and reporting required by the Sunshine provisions,” as well as time for “system development, implementation, testing, and training.”